紫光古汉生物制药2005年第三季报告(节录)
人气:
【字体:大 中 小】
发布时间:2004-10-18 19:57:49
财务资料
1、主要会计数据及财务指标
单位:(人民币)元
|
本报告期末 |
上年度期末 |
本报告期末比上年度期末增减(%) |
总资产 |
633,642,985.05 |
676,627,485.65 |
-6.35 |
股东权益(不含少数股东权益) |
267,191,339.79 |
267,508.025.77 |
-0.12 |
每股净资产 |
1.316 |
1.318 |
-0.15 |
调整后的每股净资产 |
1.23 |
1.27 |
-3.15 |
|
报告期(2005年7-9月) |
年初至报告期期末(2005年1-9月) |
本报告期比上年同期增减(%) |
经营活动产生的现金流量净额 |
7,026,396.82 |
14,698,705.42 |
|
每股收益 |
-0.004 |
0.004 |
50% |
净资产收益率(%) |
-0.31% |
0.31% |
增加0.32个百分点 |
扣除非经常性损益后的净资产收益率(%) |
-0.24% |
0.41% |
增加0.37个百分点 |
非经常性损益项目 |
金额 |
营业外收支净额 |
-282,889.68 |
合计 |
-282,889.68 |
2.1 本报告期利润及利润分配表
单位:(人民币)元 审计类型:未经审计
项目 |
2005.7-9 |
2005.7-9 |
母公司 |
合并 |
母公司 |
合并 |
一、主营业务收入 |
55,748,920.97 |
62,705,874.35 |
54,182,358.30 |
60,005,986.58 |
减:主营业务成本 |
26,884,808.17 |
32,416,959.78 |
28,427,419.74 |
32,826,935.35 |
主营业务税金及附加 |
573,211.95 |
594,689.07 |
555,836.53 |
574,689.18 |
二、主营业务利润(亏损以“-”号填列) |
28,290,900.85 |
29,694,225.50 |
25,199,102.03 |
26,604,362.05 |
加:其他业务利润(亏损以“-”号填列) |
-426,616.34 |
-426,616.34 |
-8,759.13 |
-8,759.13 |
减:营业费用 |
10,190,507.42 |
10,643,089.67 |
8,237,750.51 |
8,958,434.90 |
管理费用 |
13,526,159.89 |
14,277,506.31 |
14,651,447.07 |
15,471,310.13 |
财务费用 |
4,640,227.26 |
4,763,284.84 |
3,925,784.48 |
4,227,478.98 |
三、营业利润(亏损以“-”号填列) |
-492,610.06 |
-416,271.66 |
-1,624,639.16 |
-2,061,621.09 |
加:投资收益(亏损以“-”号填列) |
-149,431.33 |
-465,648.25 |
71,785.47 |
-45,763.58 |
补贴收入 |
- |
- |
|
|
营业外收入 |
13,903.50 |
15,923.50 |
|
7,250.40 |
减:营业外支出 |
194,250.58 |
196,990.85 |
17,753.50 |
39,471.00 |
四、利润总额(亏损以“-”号填列) |
-822,388.47 |
-1,062,987.26 |
-1,570,607.19 |
-2,139,605.27 |
减:所得税 |
- |
47,641.97 |
|
49,147.64 |
少数股东损益 |
- |
-57,648.16 |
|
-123,629.15 |
加:未确认投资损失 |
- |
230,592.60 |
|
494,516.57 |
五、净利润(净亏损以“-”号填列) |
-822,388.47 |
-822,388.47 |
-1,570,607.19 |
-1,570,607.19 |
加:年初未分配利润 |
-73,999,058.56 |
-73,999,058.56 |
-86,022,001.91 |
-86,022,001.91 |
其他转入 |
- |
- |
|
|
六、可供分配的利润 |
-74,821,447.03 |
-74,821,447.03 |
-87,592,609.10 |
-87,592,609.10 |
减:提取法定盈余公积 |
- |
- |
|
|
提取法定公益金 |
- |
- |
|
|
七、可供股东分配的利润 |
-74,821,447.03 |
-74,821,447.03 |
-87,592,609.10 |
-87,592,609.10 |
减:提取任意盈余公积 |
- |
- |
|
|
应付普通股股利 |
- |
- |
|
|
转作股本的普通股股利 |
- |
- |
|
|
八、未分配利润 |
-74,821,447.03 |
-74,821,447.03 |
-87,592,609.10 |
-87,592,609.10 |
2.2 年初到报告期末利润及利润分配表
单位:(人民币)元 审计类型:未经审计
项目 |
2005.1-9 |
2005.1-9 |
母公司 |
合并 |
母公司 |
合并 |
一、主营业务收入 |
156,667,715.86 |
175,038,824.58 |
148,409,254.91 |
163,921,860.98 |
减:主营业务成本 |
78,206,215.78 |
92,629,317.46 |
76,452,239.11 |
88,015,647.19 |
主营业务税金及附加 |
1,546,358.86 |
1,633,822.53 |
1,443,855.31 |
1,513,811.40 |
二、主营业务利润(亏损以“-”号填列) |
76,915,141.22 |
80,775,684.59 |
70,513,160.49 |
74,392,402.39 |
加:其他业务利润(亏损以“-”号填列) |
-421,708.97 |
-421,708.97 |
-5,670.06 |
-5,422.86 |
减:营业费用 |
26,012,165.81 |
27,802,770.79 |
25,001,898.25 |
27,441,476.16 |
管理费用 |
37,405,109.98 |
39,690,725.75 |
40,891,809.07 |
43,027,947.28 |
财务费用 |
11,551,584.97 |
11,912,580.82 |
11,036,356.26 |
11,980,236.84 |
三、营业利润(亏损以“-”号填列) |
1,524,571.49 |
947,898.26 |
-6,422,573.15 |
-8,062,680.75 |
加:投资收益(亏损以“-”号填列) |
-420,545.33 |
-1,182,185.11 |
-11,377.29 |
-334,558.14 |
补贴收入 |
- |
- |
- |
- |
营业外收入 |
13,903.50 |
21,678.50 |
26,767.99 |
52,179.04 |
减:营业外支出 |
297,770.44 |
304,568.18 |
117,489.68 |
160,454.67 |
四、利润总额(亏损以“-”号填列) |
820,159.22 |
-517,176.53 |
-6,524,672.13 |
-8,505,514.52 |
减:所得税 |
- |
117,065.07 |
- |
81,979.99 |
少数股东损益 |
- |
-299,055.46 |
- |
-412,564.48 |
加:未确认投资损失 |
- |
1,155,345.36 |
- |
1,650,257.90 |
五、净利润(净亏损以“-”号填列) |
820,159.22 |
820,159.22 |
-6,524,672.13 |
-6,524,672.13 |
加:年初未分配利润 |
-75,641,606.25 |
-75,641,606.25 |
-81,067,936.97 |
-81,067,936.97 |
其他转入 |
- |
- |
- |
- |
六、可供分配的利润 |
-74,821,447.03 |
-74,821,447.03 |
-87,592,609.10 |
-87,592,609.10 |
减:提取法定盈余公积 |
- |
- |
- |
- |
提取法定公益金 |
- |
- |
- |
- |
七、可供股东分配的利润 |
-74,821,447.03 |
-74,821,447.03 |
-87,592,609.10 |
-87,592,609.10 |
减:提取任意盈余公积 |
- |
- |
- |
- |
应付普通股股利 |
- |
- |
- |
- |
转作股本的普通股股利 |
- |
- |
- |
- |
八、未分配利润 |
-74,821,447.03 |
-74,821,447.03 |
-87,592,609.10 |
-87,592,609.10 |
≡ 查看、发表评论 ≡
|